Zhejiang Cancer Hospital — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Zhejiang Cancer Hospital appears in 113 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials113

Recruiting shown10

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion StudyNCT07602907 · lead sponsor · 2026-08-04

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyNCT07330544 · lead sponsor · 2025-11-24

A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast CancerNCT07455188 · lead sponsor · 2025-03-01

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.NCT06784921 · lead sponsor · 2025-02-01

Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard TherapyNCT07284836 · lead sponsor · 2025-02-01

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical StudyNCT06538896 · lead sponsor · 2024-08-20

Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung CancerNCT06562920 · lead sponsor · 2024-07-24

The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac ToxicityNCT06214195 · lead sponsor · 2024-01-20

Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast CancerNCT07014410 · lead sponsor · 2023-02-01

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABCNCT05856383 · lead sponsor · 2022-03-16

An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung CancerNCT07849712 · lead sponsor · 2026-10-01

NOT_YET_RECRUITING

Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC TherapyNCT07689929 · lead sponsor · 2026-08-01

NOT_YET_RECRUITING

Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNCT07691515 · lead sponsor · 2026-07-01

NOT_YET_RECRUITING

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain MetastasesNCT07343479 · lead sponsor · 2026-05-01

NOT_YET_RECRUITING

A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast CancerNCT07180914 · lead sponsor · 2025-10-10

NOT_YET_RECRUITING

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLCNCT06478043 · lead sponsor · 2024-10-16

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast CancerNCT06254066 · lead sponsor · 2024-04-16

NOT_YET_RECRUITING

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical TrialNCT06308939 · lead sponsor · 2024-03-08

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.NCT06195683 · lead sponsor · 2023-12-01

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.NCT06140576 · lead sponsor · 2023-11-30

NOT_YET_RECRUITING

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLCNCT06350162 · lead sponsor · 2023-10-18

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction ImmunochemotherapyNCT06031597 · lead sponsor · 2023-09-15

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.NCT06133088 · lead sponsor · 2023-08-01

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLCNCT05896059 · lead sponsor · 2023-05-15

PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC PatientsNCT05651802 · lead sponsor · 2023-01-01

Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBCNCT05550090 · lead sponsor · 2022-09-16

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNCT05461690 · lead sponsor · 2022-09-01

Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world StudyNCT05480189 · lead sponsor · 2022-08-30

NOT_YET_RECRUITING

Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer SurgeryNCT05448638 · lead sponsor · 2022-07-12

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint InhibitorsNCT05387044 · lead sponsor · 2022-05-01

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLCNCT05228496 · lead sponsor · 2022-03-17

PTC Guiding Neoadjuvant Treatment in Breast CancerNCT05103293 · lead sponsor · 2021-11-01

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast CancerNCT05075512 · lead sponsor · 2021-09-01

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLCNCT04967625 · lead sponsor · 2021-07-26

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain MetastasesNCT04808752 · lead sponsor · 2021-07-09

RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast CancerNCT04972448 · lead sponsor · 2021-07-01

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations StudyNCT05054166 · lead sponsor · 2021-05-01

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese PatientsNCT04858997 · lead sponsor · 2021-04-22

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast CancerNCT04665986 · lead sponsor · 2021-03-01

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 InhibitorNCT04691388 · lead sponsor · 2021-03-01

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast CancerNCT05030519 · lead sponsor · 2021-01-18

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBCNCT05131841 · lead sponsor · 2021-01-04

Real World Study of Bone Metastases in Patients with Advanced Breast CancerNCT06873997 · lead sponsor · 2021-01-01

Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)NCT04255836 · lead sponsor · 2020-09-30

Camrelizumab Combined With Local Treatment in NSCLC Patients With BMNCT04291092 · lead sponsor · 2020-01-01

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLCNCT04189094 · lead sponsor · 2020-01-01

Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLCNCT04161352 · lead sponsor · 2019-11-25

Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant TherapyNCT03638648 · lead sponsor · 2019-11-01

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast CancerNCT03756064 · lead sponsor · 2019-08-01

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon MutationsNCT04790409 · lead sponsor · 2019-08-01

Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint TestNCT04264468 · lead sponsor · 2019-05-14

Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBCNCT03876587 · lead sponsor · 2019-03-01

Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant ChemotherapyNCT03821454 · lead sponsor · 2019-02-01

Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast CancerNCT03618810 · lead sponsor · 2019-01-20

Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast CancerNCT03647514 · lead sponsor · 2018-12-01

The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast CancerNCT03647280 · lead sponsor · 2018-12-01

The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast CancerNCT03756090 · lead sponsor · 2018-12-01

A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast CancerNCT03280134 · lead sponsor · 2018-10-15

A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLCNCT04543890 · lead sponsor · 2018-05-01

Remifemin Preventing the Climacteric Symptoms in Breast CancerNCT03339882 · lead sponsor · 2017-01-04

Drugs studied in this sponsor's trials

32 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Zhejiang Cancer Hospital as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

docetaxel5

capecitabine4

erlotinib4

Abraxane3

cisplatin3

epirubicin3

etoposide3

tislelizumab3

docetaxel RxCUI 72962 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 5 trials capecitabine RxCUI 194000 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials erlotinib RxCUI 337525 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials Abraxane RxCUI 589511 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials cisplatin RxCUI 2555 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials epirubicin RxCUI 3995 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials etoposide RxCUI 4179 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials tislelizumab RxCUI 2677426 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials bevacizumab RxCUI 253337 · Lead sponsor in 0 linked trial(s) · 2 currently recruiting 2 trials carboplatin RxCUI 40048 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials lenvatinib RxCUI 1603296 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials palbociclib RxCUI 1601374 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials tamoxifen RxCUI 10324 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials durvalumab RxCUI 1919503 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial eribulin RxCUI 1045453 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fulvestrant RxCUI 282357 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial gefitinib RxCUI 328134 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial goserelin RxCUI 50610 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial irinotecan RxCUI 51499 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial irinotecan liposomal RxCUI 1719768 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Navelbine RxCUI 53557 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial niraparib RxCUI 1918231 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor84

collaborator29

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.